{"id":"ad-2022","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AD-2022 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. The exact molecular mechanism is still being studied.","oneSentence":"AD-2022 is a small molecule that targets the PI3K/AKT pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:12.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT06448962","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-10-22","conditions":"Hypertension, Essential, Primary Hypercholesterolemia","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AD-2022","genericName":"AD-2022","companyName":"Addpharma Inc.","companyId":"addpharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AD-2022 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}